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Background: We previously reported the results of a phase II study for patients with newly diagnosed primary central
nervous system lymphoma treated with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-
adapted whole-brain radiotherapy (WBRT). Now, we update the initial results.
Patients and methods: From 1999 to 2004, 23 patients received high-dose methotrexate. In case of at least partial
remission, high-dose busulfan/thiotepa (HD-BuTT) followed by aPBSCT was carried out. Patients refractory to induction
or without complete remission after HD-BuTT received WBRT. Eight patients still alive in 2011 were contacted and Mini-
Mental State Examination (MMSE) and the European Organisation for Research and Treatment of Cancer quality-of-life
questionnaire (QLQ)-C30 were carried out.
Results: Of eight patients still alive, median follow-up is 116.9 months. Only one of nine irradiated patients is still alive
with a severe neurologic deﬁcit. In seven of eight patients treated with HD-BuTT, health condition and quality of life are
excellent. MMSE and QLQ-C30 showed remarkably good results in patients who did not receive WBRT. All of them
have a Karnofsky score of 90%–100%.
Conclusions: Follow-up shows an overall survival of 35%. In six of seven patients where WBRT could be avoided, no
long-term neurotoxicity has been observed and all patients have an excellent quality of life.
Key words: autologous stem-cell transplantation, long-term follow-up, methotrexate, neurotoxicity, primary CNS
lymphoma
introduction
Primary central nervous system lymphoma (pCNSL) is a rare
malignant non-Hodgkin’s lymphoma of B-cell origin. Whole-
brain radiotherapy (WBRT) as the sole treatment modality is
associated with an overall response rate of up to 90% but a very
high relapse rate and a median overall survival (OS) of 1 year.
In addition, WBRT is associated with an increased likelihood
of treatment-related toxicity, especially in patients >60 years
[1]. To improve these results, WBRT has been combined with
high-dose methotrexate (HD-MTX), the most effective
chemotherapeutic agent for pCNSL. Combination of
methotrexate (MTX) and WBRT increased the 2-year survival
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from 43% to 73% [2]; however, the combination of MTX and
WBRT is associated with a high risk of delayed neurotoxicity,
primarily in elderly patients [3]. To avoid neurological deﬁcits,
we initiated a phase II study [Ostdeutsche Studiengruppe
Hämatologie und Onkologie (OSHO)-53 study] for patients
with newly diagnosed pCNSL to be treated with high-dose
busulfan/thiotepa (HD-BuTT) followed by autologous
peripheral blood stem-cell transplantation (aPBSCT) and
response-adapted WBRT after induction therapy with HD-
MTX. The results of this study were published in 2006 [4].
Here, we give a long-term follow-up after >10 years after study
initiation.
patients and methods
Twenty-three immunocompetent patients with histological diagnosis of
pCNSL received HD-MTX. Patients that achieved a complete remission
(CR) or partial remission received HD-BuTT with aPBSCT. Patients in CR
after high-dose chemotherapy received no further treatment, all others were
treated with whole-brain irradiation. Patient characteristics and the details
of the study protocol have been reported [4]. All living patients have been
contacted now to evaluate OS and Mini-Mental State Examination
(MMSE) to assess a possible cognitive deﬁciency. Maximum score for no
mental restriction is 30 points. A quality-of-life questionnaire (QLQ)-C30
was used to assess quality of life. Twenty-eight points indicate the best
possible quality of life. The number of points is inversely correlated with
the quality of life.
results
In our initial publication in 2006, we showed the results after a
follow-up range of 1–69 months [4]. Median follow-up now is
26 months (range 1.4–141). Eight of the 23 patients enrolled in
this study are still alive, while 15 patients died. Causes of death
were multiorgan failure (two patients), neurological toxicity
(three patients after WBRT), pneumonia (three patients; 3, 10,
and 47 months after diagnosis), pulmonary embolism (two
patients; 3 and 26 months after start of therapy) (Table 1).
Fatal relapses occurred in ﬁve patients. All relapses emerged
later than 12 months from diagnosis (12, 19, 19, 38, and 58
months). One testicular relapse occurred 4 months after
aPBSCT. The patient received chemotherapy (R-CHOP) and is
alive and in CR, 115 months after diagnosis of pCNSL. One
additional relapse occurred 103 months after therapy; rescue
Table 1. Patient characteristics including the results of quality-of-life measurement
Age/sex HD-BuTT WBRT Neurotoxicity LFU/status/CoD MMSE QLQ-
C30
Remarks
67/male + − − 47 months/CR, dead/pneumonia – –
58/male + + + 27 months/CR, dead/neurotoxicity – –
48/female − + + 19 months/PD, dead/relapse – –
68/female + − + 12 months/SU, dead/relapse – –
56/male − − − Day 26 after MTX/NC, dead/PE – –
63/male + + + 6 months/PR, dead/neurotoxicity – –
66/male − + + 20 months/CR, dead/neurotoxicity – –
61/female + − − 3 months/CR, dead/pneumonia – –
63/female − + + 19 months/CR, dead/relapse – –
55/male − + − 3 months/SU, dead/cardiac/PE – –
18/female + − + 10 months/CR, dead/pneumonia – –
52/male + − − 1 month/SU, dead/septic MOF – –
51/female + − − Day 6/SU, dead/septic MOF – –
52/male − + − 58 months/CR, dead, relapse – –
53/female + + + 38 months/CR, dead, relapse – –
42/female + − − 141 months/CR, alive n.e. n.e. Gall-bladder carcinoma
51/female + − − 123 months/relapse → CR, alive 24 33/28 CR after relapse, follow-up 5
months
48/male + − − 123 months/CR, alive 30 35/28
40/male + − − 118 months/CR, alive 29 28/28
60/male + − − 4 months after HDC testicular relapse, salvage
therapy/115 months/CR, alive
28 40/28
56/male + − − 79 months/CR, alive 27 40/28
54/female − + + 88 months/CR, alive 20 60/28 Severe neurological deﬁcit
69/female + − + 93 months/CR, neurological deﬁcit, alive 17a 41a/28 Lost to follow-up, last follow-up
November 2009
aData from November 2009.
CoD, cause of death; CR, complete remission; HD-BuTT, high-dose busulfan/thiotepa; HDC, high-dose chemotherapy; LFU, length/status of last follow-up;
MMSE, Mini-Mental State Examination; MOF, multiorgan failure including ventilation; MTX, methotrexate; NC, no change; n.e., not evaluable;
neurotoxicity, clinically relevant neurotoxicity; PD, progressive disease; PE, pulmonary embolism; PR, partial remission; QLQ, quality-of-life questionnaire;
SU, remission status unknown; WBRT, whole-brain radiotherapy.
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therapy (carmustine/thiotepa followed by aPBSCT) has led to a
CR lasting now for 5 months. In another patient, a carcinoma
of the gall-bladder was detected and she is still receiving
chemotherapy. The remaining six patients are in CR. The OS
and time to treatment failure, deﬁned as relapse or death due
to pCNSL or treatment-related causes of all patients, are shown
in Figure 1. The results from the questionnaires (MMSE and
QLQ-C30) are shown in Table 1. Except for one female
patient, all patients who did not receive WBRT revealed
excellent results upon examination, i.e. between 24 and 30
points in the MMSE (median 28 points) and between 33 and
40 points (median 35 points) in the QLQ-C30 with no
restriction reported in their daily life due to neurological
deﬁcits. A 69-year-old female patient with neurological deﬁcits
despite no irradiation is the oldest patient in this trial and
actually lost to follow-up. In November 2009, we were able to
carry out the tests and she showed MMSE only of 17 points
but 41 points in QLQ-C30. She needed no help to dress up,
was able to wash herself, and could independently go for a
walk. She was living with her daughter and both were quite
satisﬁed. The patient who got WBRT reached only 20 points in
the MMSE. Most of the day, she was sitting in a chair due to
severe neurological deﬁcit. She needed help to dress up, was
not able to wash herself, and was visited two times a day by a
nurse. QLQ-C30 of this patient shows 60 points, which
documents restricted quality of life, but the patient told us to
be satisﬁed with her health and quality of life. Upon univariate
analysis, we found a correlation of the length of the interval
between initial diagnosis and initiation of HD-MTX therapy
with outcome. If the period exceeded 20 days, there was a
signiﬁcantly worse OS (log-rank test, chi-square test, P = 0.046)
(Figure 2). No signiﬁcant impact of age (>/< 60 years), gender,
initial Karnofsky score (>/< 70%), initial lactate dehydrogenase
level of serum, and time between the ﬁrst and the second HD-
MTX cycle was seen.
discussion
In this article, we report a long-term follow-up of patients with
pCNSL having been treated in the OSHO-53 study. When we
started this study in 1999, the main question we wanted to
answer was whether patients with pCNSL receiving two cycles
of HD-MTX followed by HD-BuTT with aPBSCT have a
survival rate comparable with studies using chemotherapy plus
WBRT regularly. In order to achieve a high tumoricidal
impact, we have chosen a dose-dense protocol including two
cycles of HD-MTX and HD-BuTT with aPBSCT within 28
days. As shown by univariate analysis (Figure 2), it is
important to treat patients with pCNSL as soon as possible
after diagnosis. We hoped to show that by omitting WBRT,
less neurotoxicity can be observed and a better quality of life
later on can be achieved. Analyzing our data 10 years after
initiating the study, we see an OS of 35%, which is not inferior
to other studies using a combination of chemotherapy and
WBRT. Blay et al. [3] shows a 5-year survival of 19%,
Poortmans et al. [5] 58% OS after 3 years, and DeAngelis et al.
[6] 30% after 5 years. In addition, Thiel et al. [7] reported
recently no signiﬁcant difference in OS when WBRT was
omitted from ﬁrst-line chemotherapy in patients with newly
diagnosed pCNSL. In this study, a HD-MTX-based
chemotherapy was used without aPBSCT. In order to
investigate the long-term neurotoxicity in our study protocol,
we analyzed the MMSE and QLQ-C30. The patient that was
treated with WBRT because of a lack of response to HD-MTX
shows severe neurological deﬁcits. Her daily activity is
markedly reduced as described above. Results from MMSE and
QLQ-C30 show very bad results. Of the remaining seven
patients that were treated with HD-BuTT, questionnaires could
only be completed by ﬁve patients. The patient with the
recently diagnosed gall-bladder carcinoma denied to
participate. Another patient has moved to an unknown place,
but in November 2009, she ﬁlled out the questionnaires with a
bad MMSE but a good QLQ-C30 result.
As described in other studies, late relapses are not
uncommon [5, 8, 9]. We saw the latest relapse after >100
months, which underlines the importance of regular and long-
lasting follow-up, since a promising salvage therapy is available
[10–14].
One systemic relapse in the testis occurred and could be
successfully managed with R-CHOP chemoimmunotherapy.
In summary, the results of this study show that HD-MTX
with HD-BuTT followed by aPBSCT results in long-term
disease control in about one-third of the patients. Most of
Figure 1. Overall survival (OS) and time to treatment failure (TTF) of all
23 patients who had been enrolled in the study. Treatment failure was
deﬁned as relapse or death due to primary central nervous system
lymphoma or treatment-related reasons.
Figure 2. Overall survival depending on the time interval between initial
diagnosis and start of therapy with high-dose methotrexate. Log-rank test,
P = 0.046, standard error of the mean, SEM.
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them show no compromising cognitive functions and have an
excellent quality of life. These long-term results support
ongoing treatment efforts aiming to increase the tumor-
eradicating potential of primary therapy, to minimize early
mortality, and to avoid neurotoxicity due to WBRT. Adding
rituximab, cytarabine, and thiotepa to HD-MTX, the ongoing
randomized trial NCT01011920, initiated by A. Ferreri, will
help to establish a more effective therapy strategy before high-
dose chemotherapy and aPBSCT.
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